Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

NCT Number	NCT07444567
Lead Sponsor	AstraZeneca
Conditions	Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
Enrollment	230 participants
Start Date	2026-05-25
Primary Completion	2029-12-28 (estimated)
Study Completion	2029-12-28 (estimated)
Updated on ClinicalTrials.gov	2026-04-08